Welcome to our dedicated page for Pct news (Ticker: PCTL), a resource for investors and traders seeking the latest updates and insights on Pct stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pct's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pct's position in the market.
PCT LTD (OTC Pink: 'PCTL') has made significant strides in commercializing its Annihilyzer® Infection Control System within the UK’s National Health Service (NHS), as reported by NTH Solutions UK. North Tees Hospital has completed initial testing and is set to conduct a 12-week evaluation study across multiple wards, including those with COVID-19 patients. The study will follow NIHR protocols, supported by Teesside University. CEO Gary Grieco emphasized the challenges and opportunities presented by COVID-19, stating that both parties expect a successful outcome from the partnership.
PCT LTD (OTCQB: PCTL) announced a key advancement in the commercialization of its Annihilyzer® Infection Control Systems with the NHS in the UK. North Tees Hospital has completed initial testing and will begin a 12-week evaluation study in live wards, including those for COVID-19 patients. The study follows protocols from the NIHR and will be supported by Teesside University. CEO Gary Grieco emphasized the challenges and opportunities presented by COVID-19, asserting confidence in achieving successful outcomes from the partnership.
PCT LTD (OTC:PCTL) is expanding its distributor network, now totaling 21, enhancing sales and marketing efforts for its environmentally safe disinfecting product, Hydrolyte®. The company has launched a new distributor-focused website and engaged Barwicki Investor Relations to connect with over 26,500 potential investors monthly. PCTL aims to list on the OTC QB market, emphasizing sustainable technologies. Stakeholders are reminded to rely solely on official updates via press releases and the company's Twitter for accurate information, due to potential risks in achieving financial goals.
PCT Ltd. (OTC Pink: PCTL) has secured an additional $150,000 conventional, convertible loan at 5% annual interest with a fixed conversion price of $0.10/share. The funds will primarily be allocated for constructing 4 Annihilyzer® Infection Control Systems and completing 3 existing pieces of equipment. PCTL is in the final stages of preparing for its application to list on OTC:QB, addressing compliance comments from OTC Markets. Share count remains steady at 721,187,846 shares. Shareholders are reminded to rely solely on official communications for updates.
PCT LTD (OTC Pink: PCTL) announces the installation of four rack-mounted Annihilyzer® systems in a New York City hospital, with two more planned for installation in early 2021. These systems enhance disinfecting solutions critical in combating microbial infections amid the global pandemic. CEO Gary Grieco reaffirmed the company’s commitment to meet rising demand. As of November 30, 2020, there were 721,187,846 outstanding shares, with 126,187,846 restricted. The company emphasizes that all material corporate updates will be communicated solely through official press releases or SEC filings.